ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Effect of Maintaining Immunosuppression after Kidney Graft Failure on Mortality and Re-Transplantation

C. Schinstock, S. Balakrishnan, A. Bentall, M. Merzkani, M. Stegall

Mayo Clinic, Rochester, MN

Meeting: 2020 American Transplant Congress

Abstract number: 353

Keywords: Immunosuppression, Mortality, Retransplantation, Sensitization

Session Information

Date: Saturday, May 30, 2020

Session Name: Kidney Complications: Non-Immune Mediated Late Graft Failure

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

Related Abstracts
  • Associations of Estimated GFR and Urinary Protein Excretion with Mortality and Graft Failure Following Kidney Transplantation
  • Serum Phosphorus and Cardiovascular Disease Outcomes, Graft Failure, or Total Mortality in Chronic Kidney Transplant Recipients.

*Purpose: Patients with a failed renal allograft are at high risk for mortality. The potential benefit of maintaining immunosuppression with the intent to minimize sensitization must be balanced against the risk of complications. In the current era it remains unclear how to manage immunosuppression after graft failure in re-transplant candidates and clinical practices vary. Aim: To determine the association of immunosuppression maintenance and post failure outcomes including death, sensitization, and re-transplantation among patients with history of graft failure.

*Methods: We performed a single center retrospective study of patients transplanted from 10/2007 through 5/2017 who had graft failure (n=119). We collected data regarding basic demographics, immunosuppression, serial cPRA values, death, re-transplantation, and dialysis. JMPv13 was used for statistical analysis.

*Results: From 10/2007 through 5/2017, 1354 solitary ABO compatible transplants were performed and 119 of the transplants failed. Median (IQR) time to graft failure was 3.4 (1.4-5.3) years post-transplant. Of the graft failures, 9.2% (11/119) received a transplant prior to needing dialysis (preemptive) while 90.8% (108/119) started dialysis. Among the patients who started dialysis and had immunosuppression information, 45.8% (44/96) died and 20.1% (20/96) were re-transplanted over a median (IQR) follow-up of 1.3 (0.3-3.2) years of post-graft failure. Mortality and immunosuppression: Death occurred in 30.6% (11/36) of patients who discontinued immunosuppression versus 55.0% (33/60) in patients who continued immunosuppression, p=0.02. Mortality rates differed with age. Among patients aged < 65, 25.0% (8/32) died when immunosuppression was stopped and 47.8% (22/46) died when immunosuppression was maintained to some degree, p=0.04. The overall rate of death was higher in the patients aged > 65. In this group the death rate was similarly high regardless of immunosuppression [75.0% (3/4) versus 78.6% (11/14), p=0.87]. Overall, the factors associated with mortality on dialysis included immunosuppression maintenance (OR 2.8, p=0.02), female sex (OR 2.7, p =0.02), age >65 (OR 4.3, p=0.01) and Cardiovascular disease (OR 10.2, p<0.0001). Sensitization, re-transplantation, and immunosuppression: Complete immunosuppression withdrawal compared to maintenance was associated with a higher cPRA post graft failure [median 100 (IQR 94-100)] versus 65(12.5-96.5),p=0.02 but the re-transplantation rate was similar [22.2% (8/36) versus 20.0%(12/60), p=0.87].

*Conclusions: Immunosuppression maintenance after renal allograft failure is associated with increased mortality. Although withdrawal of immunosuppression is associated with increased sensitization, this does not appear to result in reduced transplantation. Therefore immunosuppression withdrawal should be considered among renal re-transplant candidates who are unlikely to receive a transplant within a short time period.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Schinstock C, Balakrishnan S, Bentall A, Merzkani M, Stegall M. Effect of Maintaining Immunosuppression after Kidney Graft Failure on Mortality and Re-Transplantation [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-maintaining-immunosuppression-after-kidney-graft-failure-on-mortality-and-re-transplantation/. Accessed April 22, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.